首页> 外文期刊>Nephron >Anaemia Management in Non-Dialysis Chronic Kidney Disease: Flexibility of Target to Target Stability?
【24h】

Anaemia Management in Non-Dialysis Chronic Kidney Disease: Flexibility of Target to Target Stability?

机译:非透析慢性肾脏病的贫血管理:靶标对靶标稳定性的灵活性?

获取原文
获取原文并翻译 | 示例
           

摘要

International clinical practice guidelines have recently recognized for the first time the concrete difficulty of keeping chronic kidney disease (CKD) patients within the narrow haemoglobin (Hb) target recommended of 11-12 g/dl (110-120 g/l) because of the variability of individual patient Hb levels. This emerging clinical problem has been the topic of several editorials that, however, exclusively focused on haemodi-alysis patients. Recently, 3 retrospective studies have been published on Hb variability in non-dialysis CKD. The studies which overall included more than 6,000 patients showed that Hb variability in non-dialysis CKD is greatly prevalent and is associated with a worse cardiorenal outcome. This minireview summarizes the results and limits of these studies and discusses the potential implications for clinical practice.
机译:国际临床实践指南最近首次认识到将慢性肾脏病(CKD)患者保持在推荐的11-12 g / dl(110-120 g / l)的窄血红蛋白(Hb)目标范围内的具体困难。个别患者血红蛋白水平的变异性。这个新兴的临床问题一直是几篇社论的主题,然而,这些社论只针对血液透析患者。最近,发表了3篇关于非透析CKD中Hb变异性的回顾性研究。总共包括6,000多名患者的研究表明,非透析CKD的血红蛋白变异性非常普遍,并伴有较差的心肾结局。这份小型综述总结了这些研究的结果和局限性,并讨论了对临床实践的潜在影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号